PepFellas Laboratories | Research-Grade Peptides
PEPFELLAS Laboratories • Est. 2026
Research Wiki / Peptide Profile
Peptide Profile

The Made Man Blend

The **Tesamorelin / Ipamorelin Co-Agonist** pairs a full-length, stabilized Growth Hormone-Releasing Hormone analogue (**Tesamorelin**) with a highly selective pentapeptide ghrelin-mimetic (**Ipamorelin**).

1. Chemical Structure and Biochemistry

This co-agonist formulation combines a large 44-amino-acid polypeptide with a compact, synthetic 5-amino-acid secretagogue.

  • Tesamorelin (TH-9507): Consists of the complete 44-amino-acid human GHRH sequence modified at the N-terminus with a trans-3-hexenoic acid group. This lipophilic cap prevents rapid enzymatic inactivation by DPP-4 and enhances receptor binding stability compared to native GHRH.
  • Ipamorelin (NNC 26-0161): A synthetic C-terminally amidated pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) derived from GHRP-1, engineered with non-natural D-amino acids and $\alpha$-aminoisobutyric acid (Aib) for high receptor selectivity and proteolytic resistance.

2. Mechanism of Action

Tesamorelin and Ipamorelin act on complementary G-protein-coupled receptors located on anterior pituitary somatotroph cells to produce a synergistic (greater-than-additive) GH pulse:

  • GHRH Receptor Activation (Tesamorelin): Binds to GHRH-R, activating the $G_s$/adenylyl cyclase/cAMP/PKA signaling cascade to stimulate both de novo growth hormone synthesis and physiological secretion.
  • GHS-R1a Receptor Activation (Ipamorelin): Selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) via the $G_q$/PLC/$IP_3$/$Ca^{2+}$ pathway, increasing GH pulse amplitude and attenuating hypothalamic somatostatin inhibition.
  • Endocrine Selectivity: Unlike older GHRPs (such as GHRP-2, GHRP-6, or Hexarelin), Ipamorelin demonstrates minimal stimulation of ACTH/cortisol, prolactin, or ghrelin-mediated hyperphagia. Downstream, elevated pulsatile hGH increases hepatic IGF-1 production while preserving endogenous negative-feedback regulation.

3. Research and Applications

Tesamorelin is FDA-approved (Egrifta) for reducing excess visceral adipose tissue (VAT) in HIV-associated lipodystrophy, while Ipamorelin remains an unapproved investigational peptide.

  • Visceral Lipolysis & Body Composition: Researched for selectively reducing deep visceral abdominal fat, improving lipid turnover, and supporting lean skeletal muscle mass preservation.
  • Recovery & Endocrine Aging: Studied in metabolic and longevity research contexts for enhancing slow-wave sleep architecture, connective tissue repair, and restoring age-related declines in GH/IGF-1 pulsatility.

Note: While Tesamorelin is clinically approved as a standalone medication for specific indications, co-formulated Tesamorelin/Ipamorelin blends are experimental research preparations and are prohibited in tested athletic competition by WADA.

Tags: Tesamorelin Ipamorelin co-agonist GHRH-analogue GHS-R1a-agonist growth-hormone-secretagogue TH-9507 NNC-26-0161 visceral-adipose-tissue lipolysis IGF-1